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J Appl Physiol 107: 1249 –1257, 2009. First published August 6,
2009; doi:10.1152/japplphysiol.91393.2008.—There is increasing
evidence that upregulation of arginase contributes to impaired
endothelial function in aging. In this study, we demonstrate that
arginase upregulation leads to endothelial nitric oxide synthase
(eNOS) uncoupling and that in vivo chronic inhibition of arginase
restores nitroso-redox balance, improves endothelial function, and
increases vascular compliance in old rats. Arginase activity in old rats
was significantly increased compared with that shown in young rats.
Old rats had significantly lower nitric oxide (NO) and higher super-
oxide (O2) production than young. Acute inhibition of both NOS,
with NG-nitro-L-arginine methyl ester, and arginase, with 2(S)-amino-
6-boronohexanoic acid (ABH), significantly reduced O2 production
in old rats but not in young. In addition, the ratio of eNOS dimer to
monomer in old rats was significantly decreased compared with that
shown in young rats. These results suggest that eNOS was uncoupled
in old rats. Although the expression of arginase 1 and eNOS was
similar in young and old rats, inducible NOS (iNOS) was significantly
upregulated. Furthermore, S-nitrosylation of arginase 1 was signifi-
cantly elevated in old rats. These findings support our previously
published finding that iNOS nitrosylates and activates arginase 1
(Santhanam et al., Circ Res 101: 692–702, 2007). Chronic arginase
inhibition in old rats preserved eNOS dimer-to-monomer ratio and
significantly reduced O2 production and enhanced endothelial-depen-
dent vasorelaxation to ACh. In addition, ABH significantly reduced
vascular stiffness in old rats. These data indicate that iNOS-dependent
S-nitrosylation of arginase 1 and the increase in arginase activity lead
to eNOS uncoupling, contributing to the nitroso-redox imbalance,
endothelial dysfunction, and vascular stiffness observed in vascular
aging. We suggest that arginase is a viable target for therapy in
age-dependent vascular stiffness.
aging; nitric oxide; S-nitrosylation; NOS uncoupling
VASCULAR STIFFNESS (33) and decreased nitric oxide (NO)
bioavailability (3, 19) are hallmarks of the aging cardiovas-
cular system. Reactive oxygen species (ROS) production is
also enhanced in aged blood vessels (12, 23). Superoxide
(O2) is a free radical that rapidly scavenges NO, thereby
decreasing NO bioavailability. NO and O2 may react to
produce peroxynitrite (ONOO), a highly damaging ROS
molecule. Thus simultaneous generation of NO and O2 can
raise ONOO to levels potentially detrimental to vascular
cell function and viability (22). This nitroso-redox imbal-
ance contributes to aging-related endothelial dysfunction
and vascular stiffness (6).
Under normal physiological conditions, nitric oxide syn-
thase (NOS) produces the potent vasodilator NO by catalyzing
L-arginine to L-citrulline. This normal function of endothelial
NOS (eNOS, NOS3) requires dimerization of the enzyme, the
substrate L-arginine, and the essential cofactor (6R)-5,6,7,8-
tetrahydro-L-biopterin (BH4) (24). However, the enzyme argi-
nase uses L-arginine as a substrate (4) and reciprocally regu-
lates NOS by substrate depletion (6, 15, 55). There is increas-
ing evidence that upregulation of arginase functionally inhibits
NOS activity and contributes to the pathophysiology of age-
related vascular dysfunction (6, 45, 55). Furthermore, pharma-
cological inhibition and antisense knockdown of arginase 1
(Arg1) restore endothelial NO production and endothelial func-
tion ex vivo (55). Interestingly, Arg1 appears to be regulated
by inducible NOS (iNOS). We have previously demonstrated
that iNOS-derived NO nitrosylates arginase at cysteine 303,
subsequently activating arginase (most likely by stabilizing the
trimeric form of the enzyme). This selective inhibition of iNOS
diminished arginase activity and significantly improved vascu-
lar function in aged vessels. Furthermore, this iNOS-dependent
activation of arginase was specific to the vascular endothelium
(45). Consequently, elevated iNOS expression in aging is
likely to precede amplified arginase activity.
Given the role of arginase in reciprocally regulating eNOS
activity and its contribution to endothelial dysfunction, in this
study, we tested the hypothesis that arginase upregulation in
old rats leads to eNOS uncoupling. Furthermore, we deter-
mined whether in vivo chronic inhibition of arginase restores
nitroso-redox balance, endothelial function, and vascular stiff-
ness in old rats to that of the young phenotype.
MATERIALS AND METHODS
Animals. Twenty-eight old (22–24 mo) and twenty-eight young
(3 mo) male Fischer 344 rats were purchased from the National
Institute on Aging and used in the study. The Fischer 344 strain has
been widely used in aging studies and has been shown by Miller et al.
(35) to have a progressive rather than an abrupt development of
age-related pathophysiology, both in differential gene expression and
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in structural alterations (35). All of the surgical procedures and
experimental protocols were approved by the Institutional Animal
Care and Use Committee and are fully accredited by the American
Association for Accreditation in Laboratory Animal Care. The reten-
tion and use of the animals are in compliance with federal, state, and
local laws and regulations and in accordance with the National
Research Council Guide.
Chronic arginase inhibition. Rats were equally divided into four
groups: 14 young control (YC), 14 young treated with arginase
inhibitor (YABH), 14 old control (OC), and 14 old treated with
arginase inhibitor (OABH). Treatment groups were given water with
2(S)-amino-6-boronohexanoicacid (ABH; 20 mg/l) (5, 21) for 25
days. Each rat consumed 400 g of ABH daily. Control groups
were given normal tap water. There was no obvious difference in the
consumption of water between the treatment and control groups. ABH
[Kd  5 nM against human Arg1 (21)] was synthesized by our
previously reported method (5), which we further optimized to facil-
itate the scale-up of inhibitor synthesis: the use of an alternative
hydroboration reagent (pinacolborane in the presence of Wilkinson’s
catalyst) increased the overall yield of the synthesis more than 10-fold
over our best previous overall yield of 4.7% (57).
Preparation of aorta and carotid artery. Heparin was administered
to the rats 1 h before death. The animals were euthanized, and the
thoracic aorta, from distal aortic arch to the diaphragmatic level, was
dissected and immersed in Krebs solution containing (in mmol) 118
NaCl, 4.7 KCl, 1.2 KH2PO4, 2.5 CaCl2, 1.2 MgSO4, 25 NaHCO3, and
11.1 glucose. Both carotid arteries were dissected and immersed in
HEPES buffer (in mmol: 136 NaCl, 5.9 KCl, 1.2 MgCl2, 11.6 HEPES,
11.5 dextrose, 1.66 CaCl2, adjusted to pH 7.4 with NaOH before
CaCl2 addition). The vessels were carefully cleaned of connective
tissue and cut into 5-mm rings. Aortic rings were prepared for use in
isometric tension ring experiments and O2 production rate. Extra
aorta tissue was immediately frozen in liquid nitrogen and stored at
80°C until assayed biochemically for arginase activity and Western
blot analysis. Carotid artery rings were used for measurement of basal
NO and O2 production rate.
Arginase activity assay. Arginase activity was measured by deter-
mining levels of urea production as previously described (55). Briefly,
rat aortic sections were sonicated for 10 min in lysis buffer (50 mmol
Tris HCl, pH 7.5, 0.1 mmol EDTA, 0.1% Triton X-100, and protease
inhibitor) and centrifuged for 30 min at 14,000 g at 4°C. Supernatant
(50 l) was then added to 75 l of Tris HCl (50 mmol, pH 7.5)
containing 10 mmol MnCl2, and the mixture was activated by heating
for 10 min at 55–60°C. The mixture was incubated with L-arginine
(50 l, 0.5 M, pH 9.7) at 37°C for 1 h, and the reaction was stopped
by adding 400 l of an acid solution (H2SO4-H3PO4-H20  1:3:7).
For colorimetric determination of urea, -isonitrosopropiophenone
(25 l, 9% in ethanol) was added, and the mixture was heated at
100°C for 45 min. After the sample was placed in the dark for 10 min
at room temperature, the urea concentration was determined spectro-
photometrically by measuring absorbance at 550 nm.
NO and ROS production in isolated rat carotid artery and aorta.
The rate of basal NO and O2 production was fluorescently measured
ex vivo in the following manner. Isolated vascular rings were cut and
pinned flat, endothelium facing up, in 35-mm culture dishes (Corning)
with a Silastic base (Sylgard 184, Dow Corning, Midland, MI). NO
production was assayed in the carotid artery using the NO-sensitive
fluorescent dye DAF FM-DA (Molecular Probes, Eugene, OR). O2
production was measured in the carotid artery or aorta using O2-
sensitive dihydroethidium bromide (DHE) (Molecular Probes). Ves-
sels were incubated for 5 min at 37°C in 2 ml of HEPES buffer
containing the appropriate dye (5 mol/l DAF-DM DA or 5 mol/l
DHE). After incubation, the buffer was replaced, and the dish was
placed in a DH-40i heating chamber (Warner Instruments, Hamden,
CT) maintained at 37°C. Time-lapse fluorescence was measured using
an epifluorescence microscope (Nikon Eclipse 80i, Tokyo, Japan),
with images recorded every 30 s using NIS Elements software
(Nikon). Rate of DAF and DHE fluorescence were measured from
the endothelium over 10 min. We also measured the rate of NO and
O2 production in response to NG-nitro-L-arginine methyl ester
(L-NAME; 100 mol/l) (Sigma-Aldrich, Buchs, Switzerland). By
plotting the fluorescence over time, the slope of the line of best fit
represents the rate of NO or O2 production. The raw fluorescence
counts and slopes were normalized by initial fluorescence counts
[in arbitrary units (au)].
Western blot analysis. Aortas from YC, YABH, OC, and OABH
animals were homogenized and centrifuged for 30 min at 14,000 g at
4°C. The protein amount of the supernatant was analyzed by the
Bradford method. Protein (100 g) from the aorta homogenate was
separated and transferred. The blots were incubated with their respec-
tive polyclonal anti-iNOS (BD Bioscience, San Jose, CA), anti-actin
(BD Bioscience), anti-eNOS (BD Bioscience), anti-Arg1 (Santa Cruz
Biotechnology, Santa Cruz, CA), or anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (Novus Biologicals, Littleton, CO) antibod-
ies, followed by a horseradish peroxidase-conjugated secondary anti-
body. Signals were detected using chemiluminescence. To quantify
the resultant blots, individual band intensities were measured (arbi-
trary units) and the iNOS-to-actin, eNOS-to-GAPDH, and Arg1-to-
GAPDH ratios were calculated per sample using ImageJ software
(National Institutes of Health). The ratios were normalized to the
mean YC ratio.
Selective fluorescent labeling of S-nitrosothiols assay. Aortas from
rats treated with ABH and untreated controls were homogenized.
S-nitrosylation of Arg1 (SNO-Arg1) was determined using the selec-
tive fluorescent labeling of S-nitrosothiols assay (44). In brief, 100 g
of proteins were blocked using 50 mM methylmethane thiosulfonate
and recovered by cold acetone precipitation. Protein samples (15 g)
were reduced with 2 mM ascorbate and labeled with Cy5 (GE
Healthcare, Piscataway, NJ). Aliquots of these samples (15 g), not
reduced, were labeled with Cy3 (GE Healthcare) to determine non-
specific labeling. Unreacted Cy dyes were removed using buffer
exchange columns, mixed, and Arg1 immunoprecipitated. Proteins
were eluted and resolved by SDS-PAGE. Gel was scanned using a
Typhoon scanner (GE Healthcare) and poststained with silver, as
previously described (44). Data for YC animals for SNO-Arg1 were
arbitrary set at 100%.
Determination of eNOS dimerization. The ratio of eNOS dimer to
eNOS monomer was determined in young, old, and OABH rats.
Dimers and monomers of eNOS were separated using low-tempera-
ture SDS-PAGE under reducing or nonreducing conditions, as previ-
ously described (50).
In vitro vascular reactivity in rat aorta. Aortic rings, prepared as
described above, were suspended from strain gauges for isometric
tension recording in organ chambers filled with 25 ml Krebs-Ringer
bicarbonate solution (95% O2-5% CO2, pH 7.4). Protocols were
performed on rings beginning at their optimum resting tone, previ-
ously determined to be 3 g for rat aorta. This resting tone was reached
by stretching rings in 500-mg increments separated by 10-min inter-
vals. Data were collected using a MacLab system and analyzed using
Dose Response Software (AD Instruments, Colorado Springs, CO).
Vessel rings were preconstricted with phenylephrine (PE; 1 mol/l)
(Sigma, St. Louis, MO), and their vasorelaxant dose responses to ACh
(1 nmol/l to 10 mol/l) (Sigma) were recorded. After washout and
return to resting tension, vessels were again preconstricted with PE,
and their response to an NO donor, sodium nitroprusside (SNP)
(Sigma), was determined (1 nmol/l to 10 mol/l).
Pulse wave velocity. In vivo vascular stiffness was determined
before and after treatment by measuring pulse wave velocity (PWV)
using an ECG-triggered 10-MHz Doppler probe (Indus Instruments,
Houston, TX) at thoracic and abdominal aorta locations. The animals
were anesthetized during the measurements with1–1.5% isoflurane.
Animals were positioned supine with limbs taped to electrocardio-
gram electrodes incorporated into a temperature-controlled printed
circuit board (THM100, Indus Instruments). Rectal temperature was
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monitored with a probe (Physitemp, Clifton, NJ) and maintained at
37°C throughout the procedure. Both thoracic and abdominal aortic
flows were acquired at a depth of 2–4 and 5–6 mm, respectively,
with a 2-mm-diameter, 10-MHz Doppler probe (Indus Instruments).
These sites of measurement were marked, and the separation distance
between them was measured. PWV (in m/s) was calculated as quotient
of separation distance and time difference between pulse arrivals, as
measured from the ECG R-peaks. Data analyses of Doppler and ECG
signals were performed off-line using DSPW software from Indus
Instruments.
Statistical analysis. Data are presented as means  SE of n
independent experiments performed from different donors. All data
were analyzed off-line with PRISM data analysis software (GraphPad
4, GraphPad Software, La Jolla, CA). A value of P  0.05 was
considered statistically significant. Arginase activity, fluorescence,
Western blot, and PWV data were analyzed with 1-way ANOVA,
Wilcoxon, and Mann-Whitney tests, as appropriate. Vascular response
data were analyzed using two-way ANOVA with Bonferroni correc-
tion for multiple comparisons.
RESULTS
Arginase activity in aorta. We first measured arginase ac-
tivity in YC, YABH, OC, and OABH groups (Fig. 1). There
was a significant increase in arginase activity in OC compared
with YC aorta (YC vs. OC: 180  16.5 vs. 270  8.5 pmol
urea mg protein1 min1; n  4, P  0.01). These results are
consistent with previous findings (6, 55) and validate the
hypothesis that arginase activity is increased in old rat vessels.
Chronic treatment of old rats with ABH significantly decreased
arginase activity compared to that shown in OC rats (OC vs.
OABH: 270  8.5 vs. 188  12.0 pmol urea mg
protein1 min1; n  4, P  0.01).
Chronic inhibition of arginase restores NO production in
carotid artery. Using a DAF-FM DA bioassay, we measured
basal NO production in YC and OC carotid arteries. OC
vessels exhibited a significant decrease in NO production
compared with that shown in YC (YC vs. OC: 2.2  0.3 vs.
0.5  0.2 au; n  6, P  0.01) (Fig. 2A). Chronic inhibition
of arginase in old rats significantly increased endothelial NO
production (OC vs. OABH: 0.5  0.2 vs. 1.9  0.1 au; n  6,
P  0.05) (Fig. 2A), suggesting that the aging-induced endo-
thelial NO production decrease is arginase dependent. Subse-
quent inhibition of eNOS with L-NAME (100 mol/l) signif-
icantly reduced NO production in YC, YABH, and OABH
animals (P  0.05 in YC, P  0.01 in YABH, P  0.01 in
OABH; n  6). OC aortas followed this trend, although the
decrease was not significant (Fig. 2C).
Acute inhibition of arginase decreases ROS production in
isolated aorta. To determine whether arginase activity contrib-
utes to eNOS uncoupling, we measured O2 production rate
using DHE fluorescence in old and young rat aortas incubated
in ABH (10 mol/l), L-NAME (100 mol/l), or with no
treatment (Fig. 3). OC vessels (n  7) exhibited a significantly
higher rate of DHE fluorescence than that shown in YC (n 
6) vessels (OC vs. YC: 4.7  0.6 vs. 2.4  0.6 au; P  0.05).
Acute inhibition of arginase significantly attenuated age-in-
duced ROS production in OC [without ABH vs. with ABH:
4.7  0.6 (n  7) vs. 1.7  0.6 (n  4) au; P  0.05], as did
#
Fig. 1. Arginase activity was significantly increased in old rats (YC vs. OC,
n  4, **P  0.01). Chronic treatment with 2(S)-amino-6-boronohexanoic
acid (ABH) inhibited arginase in old rats (OC vs. OABH, n  4, #P  0.01).
YC, young control rats; YABH, young rats treated with ABH; OC, old control
rats; OABH, old rats treated with ABH.
Fig. 2. Chronic in vivo arginase inhibition increases nitric oxide (NO) production. NO production was measured in YC, OC, YABH, and OABH carotid arteries
using a DAF-FM DA bioassay. The raw fluorescence counts and slope were normalized to initial fluorescence counts (in arbitrary units, au). A: OC vessels
exhibited significantly decreased NO production compared with that shown in YC rats (YC vs. OC: 2.2  0.3 vs. 0.5  0.2 au; n  6, **P  0.01). Chronic
arginase inhibition restores NO signaling in old rat carotid artery (OC vs. OABH: 0.5  0.2 vs. 1.9  0.1 au; n  6, *P  0.05). B: representative traces of
DAF fluorescence from YC, YABH, OC, and OABH. OC vessels exhibit a significant decrease in NO production. C: acute treatment of carotid arteries with the
nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L-NAME; 100 mol/l) leads to significant reduction in NO production in YC, YABH,
and OABH samples (*P  0.05 in YC, **P  0.01 in YABH, *P  0.05 in OABH), but the change was not significant in OC.
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NOS inhibition [without L-NAME vs. with L-NAME: 4.7 0.6
(n  7) vs. 1.8  0.6 (n  6) au; P  0.05]. In YC aortas, O2
production rates did not vary significantly with either ABH or
L-NAME (n  6, P  0.05). These results suggest that NOS
uncoupling is the source of the endothelial ROS in the aging
blood vessels, and arginase may contribute to this age-related
dysfunction.
Chronic inhibition of arginase decreases ROS production in
carotid artery. We next investigated whether chronic arginase
inhibition in old rats decreases O2 production in the carotid
artery. In support of our hypothesis, OC rats (n  7) had
significantly higher O2 production than YC rats (n  6) (OC
vs. YC: 1.9  0.3 vs. 0.8  0.2 au; P  0.05) (Fig. 4A). After
chronic administration of ABH, ROS production decreased
significantly in old vessels [OC vs. OABH: 1.9  0.3 (n  7)
vs. 0.6  0.2 (n  5) au; P  0.01], suggesting that arginase
activity is directly involved in age-induced O2 production.
ABH treatment in young rats had no significant effect on the
rate of O2 production. [for YC vs. YABH (n  5 or 6), P 
0.05]. Acute treatment of carotid arteries with the NOS inhib-
itor L-NAME (100 mol/l) led to significant reduction of ROS
production in OC (P 0.01; n 7) but not in YC, YABH, and
OABH samples (Fig. 4C). This suggests that NOS uncoupling
is the source of the endothelial ROS in the aging blood vessels.
iNOS mediates nitrosylation and activation of Arg1 in aorta
of old rats. We performed Western blot for Arg1, eNOS, and
iNOS. The expression of eNOS and Arg1 is constant in YC,
YABH, OC, and OABH groups (Fig. 5B). We confirmed our
previous finding (45) that iNOS is indeed expressed in the aorta
of old but not young rats (YC vs. OC: 1  0 vs. 1.93  0.1;
YC vs. OABH: 1  0 vs. 2.92  0; P  0.001, n  4) (Fig.
5A). We further tested the hypothesis that increased iNOS
expression contributes to SNO-Arg1, thereby increasing its
activity. SNO-Arg1 is significantly greater in OC (YC vs. OC:
100  0.6 vs. 192  31; n  3, P  0.05). Interestingly,
despite elevated iNOS abundance in old rats, ABH treatment in
old rats leads to a decrease in SNO-Arg1 (OC vs. OABH:
192  31 vs. 84.5  2.1; n  3, P  0.05) (Fig. 5C).
Chronic arginase inhibition restores eNOS coupling. We
further tested the hypothesis that inhibition of arginase would
maintain physiological eNOS function in aging rat aorta by
measuring eNOS dimer-to-monomer ratio. The ratio of eNOS
dimer to monomer in old rats was significantly decreased com-
pared with that shown in young rats (YC vs. OC: 4.3  1.0 vs.
0.5  0.2; n  5, P  0.05). Inhibition of arginase with ABH
prevented the decrease in eNOS dimer-to-monomer ratio in old
rats (OC vs. OABH: 0.5  0.2 vs. 3.3  1.0; n  5 or 6, P 
0.05) (Fig. 6), suggesting that inhibition of arginase in old rats
restores eNOS coupling by preventing monomerization.
Chronic arginase inhibition restores endothelial function in
aged rats. Because upregulated arginase activity increases
ROS production and decreases bioavailability of NO, both
Fig. 3. Acute arginase inhibition in old rats restores endothelial NOS (eNOS)
coupling. Reactive oxygen species (ROS) production was measured in young
and old rat aortas using the O2-specific fluorescent dye dihydroethidium
bromide (DHE). The raw fluorescence slopes were normalized by initial
fluorescence counts (in au). OC vessels exhibited a significant increase in ROS
production compared with that shown in YC rats [OC vs. YC: 4.7  0.6 (n 
7) vs. 2.4  0.6 (n  6) au; *P  0.05]. Arginase inhibition significantly
attenuated age-associated ROS production [OC without ABH (ABH) vs. OC
with ABH (ABH	): 4.7  0.6 (n  7) vs. 1.7  0.6 (n  4) au; *P  0.05],
as did eNOS inhibition [OC without L-NAME (L-NAME) vs. OC with
L-NAME (L-NAME	): 4.7 0.6 (n 7) vs. 1.8 0.6 (n 6) au; *P 0.05].
These results suggest that eNOS uncoupling and arginase activity are directly
linked.
Fig. 4. Chronic in vivo arginase inhibition decreases ROS production. The raw fluorescence counts and slope were normalized by initial fluorescence counts (in
au). A: ROS production was measured using the O2-specific fluorescent dye DHE in YC, YABH, OC, and OABH carotid arteries. OC rats showed a significant
increase in ROS production compared with YC rats [OC vs. YC: 1.9  0.3 (n  7) vs. 0.8  0.2 (n  6) au; *P  0.05]. Chronic arginase inhibition decreases
ROS production rate to similar level of YC [OC vs. OABH: 1.9 0.3 (n 7) vs. 0.6 0.2 (n 5) au; **P 0.01]. B: representative traces of DHE fluorescence
rate from YC, YABH, OC, and OABH. DHE production rate, indicating endothelial ROS production rate, is significantly increased in OC compared with YC
(P  0.05). C: acute treatment of carotid arteries with the NOS inhibitor L-NAME (100 mol/l) leads to significant reduction of ROS production in OC (**P 
0.01, n  7) but not significant in YC, YABH, and OABH.
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characteristics of endothelial dysfunction in our aging model,
we determined whether chronic in vivo inhibition of arginase
could attenuate this dysfunction. OC rats exhibited a signifi-
cantly impaired maximal dilator response (Emax) compared
with YC rats [OC vs. YC: Emax of 64.0  2.6% (n  7) vs.
Emax of 94.3  1.8% (n  7); P  0.01] (Fig. 7A). Chronic in
vivo inhibition of arginase with ABH in old rats restored
endothelial-dependent relaxation compared with that shown in
OC animals [OABH vs. OC: 80.3  2.4% (n  7) vs. 64.0 
2.6% (n  7); P  0.05], whereas the response in aorta from
young rats treated with ABH was not significantly different
from YC rats (n  7, P  0.05) (Fig. 7A).
The response to the endothelial-independent vasodilator
SNP shows significantly different vasodilator response at SNP
10 nmol/l in young rats (YC, YABH) compared with that
shown in old rats (OC, OABH) (P  0.05, n  7) (Fig. 7B).
However, Emax was essentially unchanged in all four groups
(OC, OABH, YC, and YABH). These results suggest that
endothelial-dependent change appears to be a major contribu-
tor to the aging-related vascular changes.
Chronic arginase inhibition restores arterial compliance.
Because arterial compliance is a marker of vascular health and
it can be modulated acutely and chronically by NO, we inves-
tigated the effect of chronic arginase inhibition on vascular
stiffness. Overall, OC had a significantly lower arterial com-
pliance (higher PWV) than control young rats [pretreatment,
OC vs. YC: 6.4  0.2 m/s (n  7) vs. 4.2  0.2 m/s (n  7);
P  0.001] (Fig. 8). After 25 days of treatment with the
Fig. 5. Inducible NOS (iNOS), eNOS, and arginase 1 (Arg1) expression were determined by Western blotting. A: expression of iNOS in OC and OABH aorta
is significantly increased compared with that shown in YC (YC vs. OC and YC vs. OABH, ***P  0.001, n  4). B: expression of Arg1 and eNOS are constant
in all groups (P  0.05, n  3). Results are representative of 3 independent experiments. C: Cy5 fluorescent signal represents Arg1 S-nitrosylation (top), Cy3
represents nonspecific labeling (none detected, data not shown), and silver stain densitometry represents Arg1 amount. Cy5/silver stain densitometry was used
to normalize the S-nitrosylation value. YC data were arbitrarily set at 100%. Data are representative of 3 independent experiments. S-nitrosylation is significantly
increased in OC (*P  0.05, n  3). Chronic in vivo arginase inhibition decreases S-nitrosylation (*P  0.05, n  3).
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arginase inhibitor, PWVs were significantly reduced in old rats
compared with that shown for pretreatment values [OABH,
pre- vs. posttreatment: 6.6  0.2 m/s (n  7) vs. 4.8  0.1 m/s
(n  7); P  0.05] and compared with OC [posttreatment, OC
vs. OABH: 6.5  0.2 m/s (n  7) vs. 4.8  0.1 m/s (n  7);
P  0.001]. In fact, ABH treatment significantly reduced
vascular stiffness in old rats toward that of young rats [post-
treatment, OABH vs. YC: 4.8  0.1 m/s (n  7) vs. 4.9  0.1
m/s (n  7); P  0.05].
DISCUSSION
The primary findings of this study are that iNOS induction
and arginase activation contribute to eNOS uncoupling in the
aged rat aortic endothelium. This arginase-induced eNOS un-
coupling leads to increased ROS production, which promotes
endothelial dysfunction and arterial stiffening. We have dem-
onstrated that in vivo chronic arginase inhibition restores
eNOS coupling and improves endothelial function and arterial
compliance in aging vasculature.
Aging itself significantly increases cardiovascular morbidity
without other risk factors. Recent studies have demonstrated
that aging promotes a proinflammatory microenvironment by
producing a wide range of cytokines (17, 52). This results in
the expression of iNOS, as observed in this aging rat model,
and is consistent with other studies (14, 18). Interestingly, this
induction of iNOS is confined predominantly, but not exclu-
sively to the endothelium (45). We previously confirmed that
enhanced endothelial iNOS mediates nitrosylation and activa-
tion of Arg1 in aorta of aging rats (45). A recent study (29)
found that iNOS specifically binds to and S-nitrosylates cyclo-
oxygenase 2, enhancing cyclooxygenase 2 catalytic activity.
Another recent study demonstrated that iNOS derived NO
S-nitrosylates and activates cytosolic phospholipase A2 in hu-
man cells (56). These studies provide evidence for the link
between nitrosylation and enzyme activation in specific “in-
flammatory” microenvironments. In an analogous manner, en-
dothelial iNOS mediates SNO and activation of Arg1 in aorta
of aging rats. Indeed, we have demonstrated that iNOS coim-
munoprecipitates with Arg1 in both lipopolysaccharide/
-IFN-
stimulated macrophage and endothelial cell lines. Moreover
the domains mediating this protein-protein interaction have
been elucidated (unpublished data).
Vascular ROS production is enhanced in aged blood vessels
(2, 12, 52, 53). There are four primary enzyme systems that
contribute to increased production of ROS in various patho-
physiological states: xanthine oxidase, NADH/NADPH oxi-
dase, eNOS, and the mitochondrial electron transport chain
(13). Although eNOS normally produces the vasoprotectant
molecule, NO, in the absence of either L-arginine or BH4,
eNOS can produce O2. This phenomenon has been referred to
as NOS uncoupling (30, 49). There is a growing body of
evidence that eNOS uncoupling in aging plays a crucial role in
the phenomenon of increased ROS production. This can be
normalized by eNOS inhibition or removal of the endothelium
(28). In support of our hypothesis, OC carotid arteries exhib-
Fig. 7. Arginase inhibition improves endothelial function in old rats. Vasodi-
lator dose responses to the endothelial-dependent vasodilator ACh (1 nmol/l to
10 mol/l) and endothelial-independent vasodilator sodium nitroprusside
(SNP; 1 mmol/l to 10 mol/l) in phenylephrine (PE; 1 mol/l)-preconstricted
thoracic aortic rings from YABH and OABH rats are shown. A: maximal
response (Emax) to ACh was significantly attenuated in OC rats [OC vs. YC:
64.0 2.6% (n 7) vs. 94.3 1.8% (n 7); **P 0.01]. Response to ACh
in OABH was significantly greater than that shown in OC rats [OABH vs. OC:
80.3 2.4% (n 7) vs. 64.0 2.6% (n 7); P 0.05], whereas the response
in aorta from YABH was not significantly different from YC rats (n 7, *P
0.05). B: in contrast, the response to the endothelial-independent vasodilator
SNP approached 100% and shows essentially unchanged Emax in all 4 groups
(OC, OABH, YC, and YABH). However, a small but significant difference in
vasodilator response is observed at 10 nmol/l SNP in young rats (YC, YABH)
compared with that shown in old rats (OC, OABH) (P  0.05, n  7).
Fig. 6. Native 4°C polyacrylamide gel electrophoresis and Western blot for
eNOS to determine eNOS dimerization in YC, OC, and OABH rats. In OC
rats, dimer bands of eNOS were significantly decreased compared with young
rats (YC vs. OC: 4.3  1.0 vs. 0.5  0.2; n  5, *P  0.05). Arginase
inhibition with ABH prevented the decrease in eNOS dimer bands in old rats
(OC vs. OABH: 0.5  0.2 vs. 3.3  1.0; n  5 or 6, *P  0.05).
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ited a significant decrease in NO production and higher O2
production than shown in YC rats. Acute inhibition of eNOS
with L-NAME led to a significant reduction of ROS production
in OC. The ratio of eNOS dimer to monomer in OC was
significantly decreased compared with that shown in YC. This
suggests that eNOS uncoupling is the source of the endothelial
ROS in the aging blood vessels. Together, these data suggest
that eNOS uncoupling is an important contributor to an age-
related endothelial dysfunction.
There are a number of potential reasons why eNOS might be
uncoupled and thus lead to increased ROS production in aging
(49). Oxidative stress may lead to excessive oxidation and
depletion of BH4, which contribute to eNOS uncoupling (36).
This is supported by the work of Delp et al. (20) in aging rat
skeletal muscle arteriole. On the other hand, the oxidation of
BH4 does not appear to be an important mechanism underlying
vasomotor dysfunction in aged mouse arteries (9). Levels of
BH4 and its oxidation products were not different between
young and aged mouse tissues. The discrepancy in these
studies might be related to the vessel type (conduit vs. small
resistant) or might be a function of species differences. Thus,
further studies are needed to determine the relative contribution
of BH4 cofactor depletion in age-dependent eNOS uncoupling.
Limited L-arginine availability also promotes uncoupling of
eNOS (10). Arginase upregulation can decrease L-arginine
concentrations and has been shown to contribute to the patho-
physiology of disease processes, such as aging (6, 7, 42, 55),
hypertension (26, 59), atherosclerosis (40, 41, 58), the erectile
dysfunction of diabetes (8), asthma (34, 60), and diabetes-
induced coronary vascular dysfunction (39).
Interestingly, eNOS abundance (14) is not significantly in-
creased in this study, and this is consistent with other studies
(16, 46, 47). Loss of eNOS activity may be an important
contributor to aging-related endothelial dysfunction despite
little change in eNOS protein content between studies. Further-
more, the abundance of Arg1 is also not significantly increased
in this study. Although in the Wistar aging model we had
demonstrated a small but significant increase in Arg1 expres-
sion (55), this appears not to be the case in the Fischer 344
model. There is however a clear increase in the abundance of
iNOS in the old rats compared with that shown in young. We
have previously demonstrated an increase in iNOS-dependent
SNO-Arg1 in aging rat aorta, which leads to an increase in the
enzymatic activity (45). Considering our current and previous
findings in aging rats, it follows that iNOS is responsible for
Arg1 nitrosylation and thus activation in the aged vasculature.
Thus our data suggest that an increase in arginase activity
contributes to eNOS uncoupling, leading to reduced NO and
augmented ROS production.
It is interesting to consider why NO as measured by DAF
fluorescence is decreased in the vasculature of aging rats
despite an increase in the expression of iNOS. We suspect that
this observation is indeed due to uncoupled NOS in which
iNOS-dependent NO might react very rapidly with O2 to form
ONOO (18, 53). It is also possible that, in the presence of
activated arginase, iNOS is itself uncoupled, leading to en-
hanced O2 and reduced NO production.
The results in Fig. 2A demonstrate that chronic arginase
inhibition with ABH can restore NO production in old vessels
to90% of young rats. In regard to the effects of chronic ABH
treatment on ROS (Fig. 4A), results demonstrate that ABH
reduces ROS levels even further. Specifically, the increased
NO would be expected to result in some degree of superoxide
scavenging, which is manifested as ROS levels below baseline.
A consequence of the enhanced NO is a more robust impair-
ment of detectable ROS compared with the NO effects.
Chronic arginase inhibition significantly improved but did
not completely restore the maximal vasorelaxant response in
aged aortic rings (80.3% OABH vs. 94.3% YC). Impaired NO
signaling as a result of arginase upregulation may be just one
of a number of mechanisms that are dysregulated in the aging
vasculature (54). Aging induces a progressive reduction in the
participation of NO, endothelium-derived hyperpolarizing fac-
tor, and prostacyclin (37). This may explain the partial resto-
ration of vasorelaxation to ACh in aging aorta by chronic
inhibition of arginase.
The response to the endothelial-independent vasodilator
SNP shows small attenuation in response at 10 nmol/l in old
rats (OC, OABH) compared with young rats (YC, YABH)
(P  0.05, n  7). This result was similar to that seen in a
previous study (48). This suggests that not only endothelial-
dependent but also endothelial-independent factors contribute
to the aged phenotype. A potential explanation could be age-
and arginase-induced vascular remodeling. Arginase activation
contributes to increased production of proline and polyamine,
which are associated with collagen and smooth muscle prolif-
eration, respectively (22). Therefore, arginase activation con-
tributes to age-dependent vascular stiffening through this
mechanism (43). Conduit arteries (aorta, carotid, iliac, femoral,
and brachial) become stiffer with age because elastin becomes
fragmented, degraded, and replaced by much stiffer collagen.
Fig. 8. Pulse wave velocities (PWVs) of individual rats before and after
treatment with the arginase inhibitor ABH for 25 days. Results for both young
and old rats are illustrated. The baseline PWV was significantly increased in
old rats compared with that shown in young rats [pretreatment, OC vs. YC:
6.4 0.2 m/s (n 7) vs. 4.2 0.2 m/s (n 7); ***P 0.001]. After a 25-day
treatment with the arginase inhibitor, PWVs were significantly reduced in old
rats compared with pretreatment values [OABH, pre- vs. posttreatment: 6.6 
0.2 m/s (n  7) vs. 4.8  0.1 m/s (n  7); *P  0.05] and compared with OC
[posttreatment, OC vs. OABH: 6.5  0.2 m/s (n  7) vs. 4.8  0.1 m/s (n 
7); ***P  0.001]. In fact, ABH treatment significantly reduced vascular
stiffness in old rats toward that of young rats [OABH vs. YC: 4.8  0.1 m/s
(n  7) vs. 4.9  0.1 m/s (n  7); P  0.05]. Placebo in YC and OC had no
effect.
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Furthermore, both proteins become stiffer as a result of cross-
linking and calcification (25). The inhibition of NOS with
L-NAME in an animal model is associated with tissue trans-
glutaminase (tTG) activation (our unpublished data), which
gives rise to small artery remodeling (38). By this mechanism,
tTG activation contributes to age-related arterial stiffness.
Although chronic arginase inhibition improves endothelial-
dependent function, it does not reverse tTG-induced cross-
linking changes in protein. Other studies are not consistent
with our finding in that the endothelial-independent vasodila-
tory response to SNP did not show any difference of EC50
between young and old rats (46, 47). Although the endothelial-
independent vasodilatory response showed a small difference
of EC50 in this study, endothelial-dependent change appears to
be the major contributor to the aging-related vascular alter-
ations.
Measures of central vascular stiffness are emerging as crit-
ical indexes of “vascular health.” Moreover, these indexes
appear to be the most sensitive predictors of cardiovascular
events, e.g., myocardial infarction (11, 31, 32), stroke (32), and
efficacy of anti-hypertensive therapy in decreasing cardiovas-
cular events (51). Very few therapies specifically targeting
central vascular stiffness have been tested (27). Our data
demonstrating that ABH decreases aortic PWV, a measure of
vascular stiffness, to that of the healthy young rats, is therefore
intriguing. This suggests that arginase may well be a critical
therapeutic target with regard to aging and vascular stiffness,
with our measurements yielding clinically promising results. In
this series of experiments, we confirmed our previous finding
that NO signaling is impaired in old rats and that this can be
restored through arginase inhibition (6, 45, 55).
In summary, the present findings demonstrate that arginase
upregulation by iNOS-dependent nitrosylation leads to eNOS
uncoupling and that in vivo chronic inhibition of arginase
restores nitroso-redox balance, endothelial function, and vas-
cular compliance in aging. Thus arginase may be a valuable
therapeutic target in age-dependent vascular stiffness.
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